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In addition to suppressing protein synthesis and activating protein degradation in skeletal 
muscle and other cell types, 5’-AMP-activated protein kinase (AMPK) is known to stimulate 
nuclear apoptosis in non-muscle cells through cleaved (activated) caspase-3, one of the final 
steps in the apoptosis cascade.  Although it is unknown whether AMPK stimulates caspase-3 
cleavage or nuclear apoptosis in skeletal muscle cells in vivo, AMPK activity and nuclear 
apoptosis are elevated at rest in aged rat skeletal muscle.  AMPK phosphorylation and activity 
are also higher in old vs. young rats and humans in response to overload or resistance exercise.  
Furthermore, older individuals display lower muscle glycogen content, a condition known to 
accentuate AMPK activity at rest and during aerobic exercise.  We hypothesized that skeletal 
muscle cleaved caspase-3 content would be higher after acute resistance exercise in older versus 
younger individuals.  Seven young (21.7 + 2.1 yrs) and 11 old (67.0 + 8.6 yrs) subjects 
performed an acute bout of leg extension resistance exercise.  Muscle biopsies were obtained 
 pre-exercise (PRE), immediately post-exercise (0P), 1-hour post-exercise (1P), and 2-hours post-
exercise (2P).  Glycogen content was measured in muscle samples, as were the phosphorylations 
(via western blot) of AMPK and acetyl-CoA carboxylase (ACC; a marker of AMPK activity). 
Procaspase-3 and cleaved (activated) caspase-3 contents were also assessed via western blot.  
AMPK phosphorylation was significantly (p < 0.05) increased in old, but not young, subjects 
immediately post-exercise.  In both age groups, AMPK activity (assessed by ACC 
phosphorylation) was elevated vs. PRE at the 0P and 1P time points, and cleaved caspase-3 
content was elevated vs. PRE at the 0P, 1P, and 2P time points.  However, there was no effect of 
exercise on procaspase-3 content in either age group, and no differences between age groups in 
AMPK activity, procaspase-3 content, or cleaved caspase-3 content at any time point.  There 
were significant, or close to significant, relationships between glycogen content and AMPK 
activity at time points PRE, 0P, and 1P regardless of age.  However, no significant correlations 
between AMPK activity and cleaved caspase-3 content were observed at any time point.   In 
summary, these data indicate that cleaved caspase-3 (e.g., caspase-3 activity) increases in 
response to acute resistance exercise in both young and old subjects.  However, exercise-induced 
AMPK activation may not be the mechanism by which this occurs.    
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 CHAPTER 1 
INTRODUCTION 
 
Sarcopenia 
 
 Sarcopenia is the age-related loss in skeletal muscle mass (Evans & Rosenburg 1991).  
Sarcopenia is a process that begins in young adulthood and continues with aging (Evans, 1995 & 
1997).  Research has shown that sarcopenia is a major factor in age-related decreases in muscle 
strength (Evans, 1993).  As an individual ages, there is a shift in overall body composition 
toward a higher level of fat mass (Borkan, Hultz, & Gerzoff, 1983).  This, in association with 
muscle loss, can lead to increases in many disorders: including hypercholesterolemia, 
atherosclerosis, hyperinsulinemia, insulin resistance, type 2-diabetes, and hypertension (Depres 
et al., 1990).  Aging is associated with declines in physical activity (PA), which have an effect on 
muscle atrophy and fat accumulation (Bortz, 1982).  Sarcopenia is also associated with greater 
losses in fast twitch fibers (type II fibers) (Rogers & Evans, 1993).  According to 2004 estimates, 
45% of the older population is sarcopenic (Janssen, Baumgartner, & Ross, 2004).  In 2000, the 
estimated direct healthcare cost resulting from sarcopenia was $18.5 billion.  Sarcopenia 
accounts for about 1.5% of total healthcare expenditure within the United States (Janssen et al., 
2004).   
 
Resistance Training 
 
Effective resistance training programs have proven to be an effective intervention for  
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delaying sarcopenia.  Resistance training has shown increases in both strength and muscle fiber 
size in the elderly population (Kryger & Anderson, 2007; Rogers & Evans, 1993).  Being able to 
maintain or even prevent sarcopenia is vital for all older individuals in order to perform most 
daily activities (Evans & Campbell 1993).  Multiple studies have demonstrated that similar 
results arise from resistance training interventions for both the young and older populations.  
Both aerobic and resistance training have proven benefits and are highly recommended, but only 
resistance training can prevent or even reverse sarcopenia (Evans, 2004).  However, it has been 
shown that resistance training does not appear to be as effective in an older population when 
compared to younger population.  This is particularly true with fast-twitch muscle fibers, which 
are more apt to age-related atrophy (Welle, 1996).  An investigation by Thomson and Gordon 
found that fast-twitch skeletal muscle hypertrophy is greatly reduced with age (Thomson & 
Gordon, 2005 & 2006).  Furthermore, inhibition of gains in force production with age has also 
been shown (Korhonen, 2006). 
 
Protein Synthesis and Degradation 
 
 Protein synthesis is the formation of proteins within the muscle and eventually leads to 
increases in fiber size and mass (Kryger & Andersen, 2007).  Protein degradation is a biological 
process by which the breakdown of cells occurs continuously; leading to decreases in both 
muscle fiber size and mass when it outweighs synthesis (Viana et al., 2008).  As a person ages, 
the balance between protein synthesis and degradation is altered in response to acute resistance 
exercise (Gordon et al., 2008).  In older populations, there is an increase in protein degradation at 
rest (Drummond et al., 2008) and after resistance exercise (Kumar et al., 2009).  It has also been 
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shown that protein synthesis decreases in old when compared to young individuals at rest. 
Mechanically induced protein synthesis within fast-twitch muscles may also be tapered with age. 
(Welle et al., 1995 & 1996a).   
 
Nuclear Apoptosis 
 
 Apoptosis is a biological process that follows a specific plan and design that ultimately  
leads to programmed death in mono-nucleated cells (Kerr, Wyllie, & Currie, 1972).  Apoptosis 
involves controlled processes that regulate specific genes.  These genes coordinate events that 
trigger certain signaling pathways leading to the execution and implementation of cellular 
apoptosis. Three signaling pathways have been identified, including mitochondria-mediated, 
ligand-mediated, and endoplasmic reticulum stress-mediated (Danial, Korsmeyer, 2004).  
Apoptosis was previously proposed to only be responsible for the destruction of intact cells; 
therefore, most investigations have primarily dealt with mitotic single nucleated cell types. 
Research involving apoptotic components regarding postmitotic multinucleated cells, such as 
skeletal myofibers, is not entirely developed.  It has been hypothesized that there is a link of 
apoptotic events working at the nuclear level with multinucleated skeletal myofibers and this 
process has been termed “nuclear apoptosis” (Allen, Roy, & Edgerton, 1999).  Signaling 
pathways concerning muscle myofibers can be classified into either caspase-dependent or 
caspase-independent cascade of apoptotic markers (Siu, 2009).  Apoptotic markers are divided 
into two primary types of apoptotic proteins, which are termed pro-apoptotic and anti-apoptotic 
respectively (Quadrilatero et al., 2009).  It is these proteins that may be affected by acute  
exercise and age (Siu, 2009).  
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Relation to Aging & Exercise Response 
 
 Apoptosis may play a definitive role in the development of sarcopenia.  Muscle growth 
depends on the balance between the addition of myonuclei via satellite cells versus apoptosis of 
pre-existing nuclei (Allen, Roy, & Edgerton, 1999).  Additionally, the apoptotic response to 
exercise may also effect muscle growth in older individuals.  Aged skeletal muscle may lead to 
an increased level of these apoptotic events (Leeuwenburgh et al., 2005).  According to present 
investigations, there are multiple apoptotic proteins that have been proven to be responsive to 
aging.  These include Bax, Bcl-2, multiple caspases, and other apoptotic mediators such as 
cytochrome c and apaf-1 (apoptotic protease activating factor).  Bax is a pro-apoptotic protein 
and Bcl-2 is an anti-apoptotic protein (Duronio, 2008).  Both Bax and selective caspase (caspase-
8 and -9) activities are increased in gastrocnemius and plantaris of aged rats when compared to 
young adult rats (Alway et al., 2002 & 2003).  Caspase-3 is one of the effector caspases that 
leads directly to cell destruction (Kocturk et al., 2007).  Procaspase-3 (32kD) acts as the inactive 
form, where as cleaved caspase-3 (19kD) is the active form (Siu, 2009).  Most previous literature 
refers to the 32kD form of caspase-3 as caspase-3 or total caspase-3; however, for the purposes 
of this document, it will be referred to as procaspase-3.  In addition, the 19kD or activated form 
of caspase-3 will be referred to as cleaved caspase-3. 
 The apoptotic signaling response to resistance exercise in aged skeletal muscle is 
unknown.  However, because acute resistance is not fully effective in older individuals (Welle, 
1996, Thomson & Gordon, 2005, 2006, & Korhonen, 2006), and apoptotic signaling is elevated 
in older skeletal muscle (Leeuwenburgh et al., 2005), we hypothesize that pro-apoptotic 
signaling will be greater in response to resistance exercise in aged skeletal muscle.  According to  
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Kocturk at al., cleaved caspase-3 activity increased when stimulated by a bout of strenuous 
running in young rats (Kocturk et al., 2007).   
 
AMPK 
 
5’-adenosine monophosphate (AMP)-activated protein kinase (AMPK) is an enzyme that  
acts as an intracellular sensor and is activated in response to elevated AMP/adenosine tri-
phosphate (ATP) and inorganic phosphate (Pi)/phosphocreatine (PCr) ratios.  In skeletal muscle, 
AMPK is also activated by low glycogen content (Wojtaszewski et al., 2003).  AMPK attempts 
to maintain energy stores within the cells to create homeostasis (Hardie, 2004).  AMPK may 
suppress protein synthesis and activate protein degradation.  Evidence also suggests AMPK 
phosphorylation in response to resistance training has been shown to cause a prolonged elevation 
in association with age in humans (Drummond et al., 2008).  
 The elevated AMPK activation in aged skeletal muscle may result from lower glycogen 
content. The caloric intake between elders and their young counterparts differ significantly.  The 
elderly consume much fewer carbohydrates and fats, as well as having an overall lower daily 
caloric intake.  The elderly and young differ in both amount of calories and macronutrients 
consumed during meals and snacks (Wurtman, 1988).  A decrease in carbohydrate consumption 
leads to a decrease in muscle glycogen levels in the elderly (Cartee, 1994).  This decrease in 
muscle glycogen may lead to increases in AMPK levels at rest and after resistance exercise.  It 
has also been shown that AMPK activity is higher in a glycogen-depleted state when compared 
to a glycogen-loaded state (Wojtaszewski et al., 2003).   Therefore, increases in AMPK may 
cause protein degradation, decreased hypertrophy, and decreased strength gains among the  
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elderly (Thomson & Gordon, 2005).  AMPK inhibits overload-induced hypertrophy in  
fast-twitch muscle (Gordon et al., 2008).   
 AMPK’s role in nuclear apoptosis is still somewhat vague based on present research.  
Although AMPK’s role in multinucleated skeletal muscle cells is still being investigated, it does 
seem to play a role in apoptotic signaling in mononucleated muscle cells (Dyck & Lopaschuk, 
2006; Niesler, Myburgh, & Moore, 2007).  AMPK’s role in skeletal muscle fibers may be more 
associated with fiber atrophy, as opposed to fiber death (Dirks et al. 2006).  It has been proposed 
that AMPK is pro-apoptotic in aged skeletal muscle and may play a role in age-related increase 
in apoptotic nuclei (Dyck & Lopaschuk, 2006).  Investigations have shown that activation of 
AMPK (AICAR or other common activator) can lead to increases in procaspase-3 activity in 
non-muscle cells (Sai et al., 2006; Riboulet-Chavey et al., 2008; Jung et al., 2010).  In addition, 
an investigation by Kim et al. found that inhibition of AMPK suppresses cleaved caspase-3 (e.g. 
activated caspase).  Therefore, AMPK activation may be a positive regulator of apoptosis (Kim 
et al., 2009).  We already have preliminary data from the Gordon laboratory that shows both Bax 
and procaspase-3 contents were increased with 1 week of AMPK stimulation (AICAR) (Gordon 
Unpublished). 
   
Specific Aim 
 
 Advancing age is associated with skeletal muscle fiber atrophy and is specific to the fast- 
twitch muscle fibers (Evans & Rosenburg 1991; Rogers & Evans, 1993).  Furthermore, fast-
twitch skeletal muscle hypertrophy is reduced with age (Thomson & Gordon, 2005 & 2006).  
Muscle glycogen levels are also lower within the elderly population (Cartee, 1994).  An 
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investigation by Wojtaszewski et al. found that depleted muscle glycogen levels activate AMPK 
(Wojtaszewski et al., 2003).  In addition, AMPK activity is higher following acute resistance 
training with aged skeletal muscle (Drummond et al., 2008).  Elevated AMPK activation may 
cause an elevated pro-apoptotic response to resistance exercise in aged skeletal muscle.  
Therefore, the purpose of this study was to examine the response of cleaved (activated) caspase-
3 to acute resistance exercise in the skeletal muscles of young versus old subjects.  It was 
hypothesized that skeletal muscle cleaved caspase-3 content would increase in response to acute 
resistance exercise.  It was further hypothesized that skeletal muscle cleaved caspase-3 content 
would be higher after acute resistance exercise in older versus younger individuals.  
 
 CHAPTER II  
REVIEW OF LITERATURE 
 
Sarcopenia 
 
 Aging is associated with notable alterations in body composition.  Sarcopenia, which is 
the age-related loss in muscle mass, is a notorious part of these changes (Evans & Rosenburg, 
1991).  Sarcopenia is the result of decreases in both fiber number, size, and is specific with losses 
in fast twitch fibers (type II fibers) (Rogers & Evans, 1993; Welle, 2002).  Some estimations 
state that anywhere from one-quarter to one-half of the population over the age of 65 have 
sarcopenia (Baumgartner et al., 1998).  A continual decline in muscle mass is most often seen 
after the age of 45 years (Hudges et al., 2001).  According to past investigations, sarcopenia has 
resulted in 14% of muscle loss and 34% muscle protein loss between the ages of 25 and 75.  It 
has been determined that body fat can increase from 18 to 36% in women and 33 to 44% in men 
(Cohn et al., 1980).  Sarcopenia is associated with age-related losses in metabolic rates, bone 
mineral density, strength, functional status, and daily caloric needs (Evans & Rosenburg, 1991).   
 Sarcopenia is highly correlated with physical disability within the elderly and can lead to 
multiple health concerns and healthcare expenditures (Janssen, Baumgartner, & Ross, 2004; 
Janssen et al., 2004).  The combination of muscle loss and fat gain can lead to increases in many 
disorders: including hypercholesterolemia, atherosclerosis, hyperinsulinemia, insulin resistance, 
type 2-diabetes, and hypertension (Depres et al., 1990).  Sarcopenia also plays a profound role in 
increased healthcare costs.  In 2000, healthcare costs linked to diseases associated with 
sarcopenia were $18.5 billion (Janssen et al., 2004).  This amount accounted for about 1.5% of 
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the United States total healthcare cost (about $1.3 trillion) for 2000.  With such a high incidence 
of expenditure and age-related physical disability, it is vital to examine specific mechanism(s) 
underlying sarcopenia.  Furthermore, it is necessary to examine potential compensatory methods, 
such as resistance training, to decrease the effects of increasing age on skeletal muscle mass and 
overall strength.   
 
Resistance Training 
 
 The effects of sarcopenia are clearly evident, thus allowing compensatory methods such 
as resistance training to increase in popularity.  Resistance training interventions have proven to 
be beneficial and can provide increases in both muscle strength and cross-sectional area of the 
muscle fiber (Kryger & Anderson, 2007; Rogers & Evans, 1993).  However, fast-twitch fiber 
hypertrophy associated with resistance training is significantly reduced with age (Kosek et al., 
2006; Trappe et al., 2001).  Investigations have shown that even when fast-twitch hypertrophy is 
witnessed with resistance training, it is delayed when compared to slow-twitch fibers (Pyka et 
al., 1994).  Others have shown that fast-twitch hypertrophy is still absent in the elderly even after 
one year of an appropriate intervention (Taaffe et al., 1996).  Therefore, this impaired ability to 
hypertrophy in older individuals indicates that resistance-training interventions are not 100% 
effective (Welle, 1996).  Previous investigations have also provided evidence suggesting that 
aged skeletal muscle from animal models have a weaker ability to respond to loading-induced 
muscle growth or regeneration from injury (Thomson & Gordon, 2005).  Maintaining or even 
preventing muscle atrophy associated with aging is vital for all older individuals.  The 
diminished effect of resistance training with the elderly can lead to an assortment of conditions, 
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including sarcopenia, type II diabetes, coronary artery disease, hypertension, and osteoporosis 
(Evans & Rosenburg 1991).  Therefore, it is imperative to further investigate the possible 
mechanisms that may be associated with this diminished effect of resistance training among the 
elderly.   
 
Protein Synthesis and Degradation 
 
 Protein synthesis is the formation of proteins, which leads to increases in muscle fiber 
size and mass of proteins within cells (Kryger & Andersen, 2007).  Protein degradation is the 
continual breakdown of cells.  Therefore, when degradation outweighs synthesis, there is a 
decrease in both muscle fiber size and mass (Viana et al., 2008).  Aging alters the balance 
between synthesis and degradation in response to acute resistance exercise (Gordon et al., 2008).  
Investigations have shown that there is an increase in protein degradation at rest and after 
resistance exercise with the elderly (Kumar et al., 2009; Drummond et al., 2008).  Additionally, 
there is a decrease in synthesis at rest in elderly when compared to young individuals.  It may 
also be evident that protein synthesis within fast-twitch muscle is tapered with age (Welle et al., 
1995 & 1996a).  Mammalian target of rapamyacin (mTOR) is an upstream signaling pathway 
that is associated with controlling protein synthesis and is decreased with age (Thomson & 
Gordon, 2005).  Therefore, mTOR inhibition can play a definitive role in skeletal muscle atrophy 
(Bodine et al., 2001). 
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Nuclear Apoptosis 
 
 Cellular apoptosis is cell destruction that follows a formulated plan and design in order to  
fulfill specific intentions (Kerr, Wyllie, & Currie, 1972).  Signaling pathways intervene specific 
signaling transduction leading to the execution and implementation of cellular apoptosis.  These 
pathways include mitochondria-mediated, ligand-mediated, and endoplasmic reticulum stress-
mediated (Danial & Korsmeyer, 2004).  Most investigations have primarily dealt with mitotic 
single nucleated cell types, thus apoptotic components regarding postmitotic multinucleated 
cells, such as skeletal myofibers, are not entirely developed (Siu, 2009).   
 In single nucleated cells, apoptosis manages to eliminate nuclei, which leads to the 
destruction and eventual cell death.  Multinucleated cells, such as skeletal muscle myofibers, can 
undergo losses of one or more nuclei, without complete destruction.  Furthermore, there is a 
proposed physiological link of apoptosis in muscle adaptations and refers to the apoptosis-
mediated down-regulation of the number of nuclei within the actual myofiber.  This has become 
known as “nuclear apoptosis”.  Therefore, not all myonuclei within the muscle fiber become 
apoptotic during muscle atrophy (Allen, Roy, & Edgerton, 1999).  It has been hypothesized that 
the addition of new nuclei is necessary for muscle hypertrophy and the removal of myonuclei is 
required for muscle atrophy.  It has been demonstrated that muscle hypertrophy can be promoted 
by the activation of myogenic satellite cells (Allen, Roy, & Edgerton, 1999; Charge & Rudnicki, 
2004).  Signaling pathways concerning muscle myofibers can fall into either an intrinsic or 
extrinsic pathway, which are affected by numerous apoptotic markers (proteins) and proteolytic 
enzyme activity.   
 Apoptotic markers are divided into two primary types of apoptotic proteins, which are  
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termed pro-apoptotic and anti-apoptotic, respectively.  Present investigations have uncovered 
several apoptotic markers responsive to aging, including the pro-apoptotic markers Bax, AIF 
(apoptosis inducing factor), and Smac (second mitochondria-derived activator of caspases).  In 
addition, some anti-apoptotic markers have also been investigated.  These include Hsp70 (heat 
shock protein), XIAP (X-linked inhibitor of apoptosis protein), ARC (apoptosis repressor with 
caspase recruitment domain) and Bcl-2.  Furthermore, a cascade of proteolytic enzymes known 
as caspases also play a vital role in nuclear apoptosis.  Caspase-9, which is the most upstream 
member of the apoptotic protease cascade, mediates the mitochondria-associated apoptotic 
events; therefore, activating caspase cleavage.  The activation of these caspases leads to the 
morphological changes that occur during apoptosis.  More specifically, caspase-9 leads to the 
cleavage of procaspase-3 (32kD) to cleaved (active) caspase-3 (19kD) (Siu, 2009).  As 
previously stated, most previous literature refers to the 32kD form of caspase-3 as caspase-3 or 
total caspase-3; however, for the purposes of this document, it will be referred to as procaspase-
3.  In addition, the 19kD or activated form of caspase-3 will be referred to as cleaved caspase-3.  
This cascade of downstream caspases carries out the final destructive processes of apoptosis (Li 
et al., 1998 & Quadrilatero et al., 2009).  A number of the above specific markers that may be 
affected by acute exercise and age (Siu, 2009) (See Figure 2. Below)    
 
Relation to Aging and Exercise Response 
 
 Apoptotic markers may play a definitive role in the development of sarcopenia.  Aged 
skeletal muscle may also lead to increases in apoptotic events (Leeuwenburgh et al., 2005).  
According to Jejurikar at al., satellite cells from old rats have greater responses to pro-apoptotic 
proteins and caspases (Jejurikar et al., 2006).  Bax, caspase-8, and caspase-9 levels are increased 
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in the gastrocnemius and plantaris of aged rats when compared to young rats (Alway et al., 2002 
& 2003).  It has been shown that 12 weeks of treadmill exercise training can alter apoptotic 
markers, such as increases in Bcl-2 and decreases in Bax in aged skeletal muscle (Song, Kwak,  
 
Figure 2.1.  Activation of caspase cascade leading to apoptosis 
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& Lawler, 2006).  One investigation found no acute changes in caspase activity or apoptotic 
markers following a single bout of prolonged moderate-intensity aerobic exercise (Quadrilatero 
et al., 2009).  Another investigation found that both pro and anti-apoptotic proteins are affected 
by age in rat fast-twitch skeletal muscle.  Additionally, caspase activity and apoptotic index were 
also increased in aged rat fast-twitch skeletal muscle. (Pistilli, Jackson, & Always, 2006).  Both 
caspase-9 and procaspase-3 have been shown to be elevated with age; therefore, these elevations 
are associated with the progression of sarcopenia (Baker & Hepple, 2006).  
A study by Yang et al. showed that the Bax/Bcl-2 mRNA ratio increases in response to 
acute resistance exercise.  This investigation showed increases in procaspase-3 mRNA in 
response to acute resistance exercise (Yang, Jemiolo, & Trappe, 2006).  A study by Mahoney et 
al., showed Bcl-2 mRNA increases with aerobic exercise (Mahoney et al., 2005).  An 
investigation by Kocturk et al. has shown that cleaved caspase-3 activity increases up to 3 hours 
post-aerobic exercise and that apoptotic responses are different when compared to different 
muscle types and oxidative metabolisms in young rats (Kocturk et al., 2007).  Similar 
investigations have shown that age-related apoptosis has the potential to be reversed with 
effective exercise interventions.  Procaspase-3 can be attenuated with exercise training (Marzetti 
et al., 2008).   
 
Upstream Signaling Pathways 
 
 There are multiple upstream signaling pathways and protein kinases that stimulate 
nuclear apoptosis.  One of the main contributors is Akt (protein kinase B), which acts as an 
apoptosis inhibitor and cell survival promoter.  Akt has the ability to block multiple pro-
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apoptotic markers; thus regulating cell survival.  When Akt phosphorylation fails, the Akt 
pathway fails to regulate or maintain normal levels of anti-apoptotic proteins.  This can lead to 
both signal interruption and multiple cellular system disruptions.  These include disruption of 
protein synthesis and anti-apoptotic signals, which can lead to a higher expression of pro-
apoptotic markers.  These markers include Bax, Bim, and Puma, which are a result from 
FOXO3A (forkhead box O 3a) activation.  FOXO3A is regulated (inhibited) by the P13K 
(phosphoinositide 3-kinase)/Akt pathway (Duronio, 2008).  Furthermore, an investigation by 
Duronio found that Akt phosphorylates (deactivates) the pro-apoptotic protein Bad (Bcl-2/Bcl-
XL-associated death domain protein) (Duronio, 2008).  An investigation by Creer at al., found an 
increase in Akt phosphorylation following resistance exercise (Creer et al., 2005).  Lastly, an 
investigation by Drummond et al., found that the Akt response (acute) to resistance exercise is 
diminished with age (Drummond et al., 2008). 
 
AMPK 
5’-adenosine monophosphate (AMP)-activated protein kinase is an energy sensor that  
attempts to maintain cellular energy stores and is activated in response to elevated AMP/ATP 
and Pi/PCr ratios.  In muscle cells, AMPK activation leads to the stimulation of glycogen 
storage, mitochondrial biogenesis, and glucose/lipid catabolism.  AMPK stimulation also 
increases with lower glycogen content (Wojazewski et al., 2003).  Furthermore, AMPK 
activation inhibits energy-consuming processes, such as fatty acid and protein synthesis (Hardie, 
2004).  Research has shown that AMPK phosphorylation suppresses protein synthesis and 
activates protein degradation.   
 AMPK activation occurs 1-2 hours after acute resistance exercise in humans; therefore, it  
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may suppress early translational signaling leading to protein synthesis.  In rat skeletal muscle 
AMPK has been shown to suppress Akt phosphorylation (Bolster et al., 2002).  AMPK’s role 
with aged fast-twitch muscle may focus on the inhibition of mTOR and suppression of some 
specific downstream translational signaling intermediates (Thomson & Gordon, 2006).  In terms 
of degradation, AMPK stimulates both atrophy-related FOXO (forkhead box) genes (especially 
the transcription factors FOXO1 and FOXO3A) and muscle-specific ubiquitin ligase genes, such 
as muscle atrophy F-box (MAFbx, or Atrogin-1) and muscle ring finger 1 (MuRF1) (Nakashima 
& Yakabe, 2007).  It is believed that AMPK activation in aged skeletal muscle is elevated and 
that it plays an integrative role with atrophy and inhibition of overload-induced hypertrophy in 
fast-twitch fibers (Gordon et al., 2008).  Additionally, AMPK phosphorylation has been shown 
to be higher in aged skeletal muscle in rats during rest and chronic overload (Thomson & 
Gordon, 2005), as well as in response to acute resistance exercise within elderly men 
(Drummond et al., 2008).  
 AMPK’s involvement with nuclear apoptosis is still being investigated.  However,  
AMPK does seem to play an integrative role in pro-apoptotic signaling in mononucleated cells 
(Dyck & Lopaschuk, 2006; Niesler, Myburgh, & Moore, 2007).  It has also been proposed that 
AMPK is pro-apoptotic in aged skeletal muscle and may be involved in the age-related increase 
in apoptotic nuclei (Dyck & Lopaschuk, 2006).  Some investigations have shown that AMPK 
activation can initiate specific markers, such as p38 and MAPK (mitogen activated protein 
kinase), which can lead to a cascade of events leading to apoptosis. Therefore, AMPK activation 
may play a role in age-related apoptosis, by means of energy depletion (Dirks et al., 2006).   
Recent investigations have shown that activation of AMPK (AICAR or other common  
activators) leads to increases in procaspase-3 activity (Sai et al., 2006; Riboulet-Chavey et al.,  
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2008; Jung et al., 2010).  Moreover the inhibition of AMPK activation can suppress both 
procaspase-3 and cleaved caspase-3 activity within non-muscle cells (Kim et al., 2009 & Khanal 
et al, 2011).  A study by Riboulet-Chavey et al. found a fourfold increase in cleaved-caspase-3 
after a period of incubation with an AMPK activator (Riboulet-Chavey et al., 2008).  Therefore, 
these data provide evidence that AMPK activation alone may be a positive regulator of 
apoptosis, specifically elevating skeletal muscle cleaved caspase-3.  Furthermore, we have 
preliminary data that show increases in skeletal muscle Bax and procaspase-3 contents when 
AMPK is stimulated for 1 week.  Additionally, we also have data that show a decrease in Bcl-2 
with 1 week of AMPK stimulation (Gordon Unpublished). 
 
AMPK, Glycogen, and Aging 
 
The diet of the elderly differs significantly from that of their younger counterparts.  
Elderly have a lower total caloric intake and consume lower amounts of both carbohydrates and 
fats (Wurtman, 1988).  There is also an inverse relationship between dietary intake and age 
among the elderly (Sonn, Rothenberg, & Steen, 1998).  This may account for the fact that there 
is a decrease in carbohydrate consumption which leads to decreases in muscle glycogen levels 
with aging (Cartee, 1994).  When muscle glycogen levels decrease in young individuals, AMPK 
levels increase at both rest and after exercise.  Investigations have shown that AMPK 
phosphorylation is higher in a glycogen-depleted state in comparison with a glycogen loaded 
state in young individuals (Wojtaswewski et al., 2003).  Muscle glycogen content following 
acute resistance exercise needs further investigation when associated with aging.  However, since 
aged skeletal muscle has lower glycogen levels (Cartee, 1994), as well as elevated AMPK 
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phosphorylation and activity than young skeletal muscle (Thomson & Gordon, 2005 & 
Drummond et al., 2008), additional decreases in glycogen following resistance exercise would 
further stimulate AMPK activation.   
 
Specific Aim 
 
 Skeletal muscle atrophy, in association with aging, is specific to fast-twitch muscle 
fibers, and hypertrophy of these muscles is diminished with an overloading stimulus such as 
resistance training (Kosek et al., 2006; Thomson & Gordon, 2005; Rogers & Evans, 1993; Evans 
& Rosenburg 1991).  These decreases in fiber size and strength may be partially due to increases 
in apoptotic markers that lead to nuclear apoptosis (Sui, 2009; Allen et al., 2003).  Nuclear 
apoptosis is also elevated within aged skeletal muscle (Leeuwenburgh et al., 2005).  AMPK 
phosphorylation is elevated in response to acute resistance exercise in aged human skeletal 
muscle (Drummond et al., 2008) and has been shown to lie upstream of caspase-3 cleavage 
(activation) and nuclear apoptosis in other cell types (Kim et al., 2009; Khanal et al, 2011; 
Riboulet-Chavey et al., 2008).  Decreases in muscle glycogen associated with aging have been 
observed (Cartee, 1994), and depleted glycogen can activate AMPK (Wojtazewski et al., 2003), 
thus leading to the possibility of increasing specific apoptotic markers.  Procaspase-3 activity 
increases within the first 0-3 hours after acute running exercise in young rats (Kocturk et al., 
2007); however, the response to resistance exercise is currently unknown, especially in young 
versus old human skeletal muscle.  Therefore, the purpose of this study was to examine the 
response of cleaved (activated) caspase-3 to acute resistance exercise in the skeletal muscles of 
young versus old subjects.  It was hypothesized that skeletal muscle cleaved caspase-3 content 
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would increase in response to acute resistance exercise.  It was further hypothesized that skeletal 
muscle cleaved caspase-3 content would be higher after acute resistance exercise in older versus 
younger individuals.  
 
  
  
 CHAPTER III 
METHODS 
 
Subjects 
 
 There were a total of 18 subjects used for this study.  There were 11 old subjects (5 male 
and 6 female), ranging from 55-85 years old and 7 young subjects (4 male and 3 female), ranging 
from 18-30 years old.  Subjects were healthy men and women with no history of hypertension, 
cardiovascular disease, or diabetes.  Subjects were non-smokers and were not on any 
medications that would alter glucose regulation.  All potential subjects were screened prior to the 
study to determine, height, weight, age, exercise history, and medical history.  Subjects were 
recruited through word of mouth, flyers, and East Carolina University mass emails.   
 
Table 3.1. Subject Characteristics 
 Young Adults (n=7) Old Adults (n=11) 
Age (years) 21.7 ± 2.1 67.0 ± 8.6 
BMI (kg/m2) 23.5 ± 3.1 29.0 ± 3.2 
Body Fat (%) 21.9 ± 5.0 32.6 ± 4.0* 
Weight (kg) 75 ± 14 85 ± 11* 
 
Table 3.1.  Body mass index (BMI) was not significantly different between groups.  The young 
and old groups differed significantly in body fat (%) and weight (kg).   
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Experimental Design 
 
The purpose of this study was to examine the response of cleaved (activated) caspase-3 to 
acute resistance exercise in the skeletal muscles of young versus old subjects.  It was 
hypothesized that skeletal muscle cleaved caspase-3 content would increase in response to acute 
resistance exercise.  It was further hypothesized that skeletal muscle cleaved caspase-3 content 
would be higher after acute resistance exercise in older versus younger individuals.    
 
Table 3.2. Subject Visitations 
Initial Visit 
1) Informed consent & medical history 
2) Height and weight measurements 
3) 4-site skinfold measurements 
4) 10-repetition maximum determination 
Experimental Session (overnight fast) 
Exercise Session 
 Bilateral leg extension 
 3 warm-up sets (50, 70, &90% of 10RM) 
 3 sets to failure (100% of 10 RM) 
Muscle Biopsy-alternating legs 
 pre-exercise, immediately post (0 minutes), 
60 minutes post, & 120 minutes post 
 
Table 3.2. 10-repetition maximum (10 RM) was determined using the leg extension machine in 
the East Carolina University FITT building.  The warm-up sets comprised of 10 repetitions, 5-7 
repetitions, and 3-5 repetitions for each respective set (50, 70, and 90% of the estimated 10 RM).  
The 0 minute time point was immediately (within 60-90 seconds) following the resistance 
exercise.  60 minutes and 120 minutes post were acquired 1 and 2 hours after the 0 minute post-
exercise biopsy, respectively.    
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Initial Visit 
 
 The initial screening took take place at the Fitness Instruction, Testing, and Training 
(FITT) building at East Carolina University.  The screening included baseline measurements, 
familiarization with the resistance exercise equipment, and determination of a 10-repetition 
maximum (10 RM) on the Cybex leg extension machine for each subject.  
 During the initial visit, participants completed all the necessary paper work.  This 
included informed consent, the dietary log, and medical history.  Height, weight, and skinfolds 
were also taken.  A 4-site skinfold method (bicep, tricep, suprailiac, subclavical) was used.  Each 
subject’s body density was estimated using the Durnin and Womersley skinfold assessment and 
body density formula ([495/(1.1714-.063 x LOG [sum of skinfolds] - 0.000406 x [age]) – 450]) 
(Durnin & Womersley, 1974).   
 Upon completion of the initial paper work, assessment, and measurements, the 10 RM 
was determined on the Cybex leg extension machine.  Prior to the 10 RM testing, each subject 
became familiar with the machine in order to reduce the risk for possible cardiovascular events 
and injury.  Additionally, each subject was asked to predict the maximum amount of weight they 
could lift 10 times.  A warm-up period consisting of 50% of their 10 RM was also used.  After 
completion of the warm-up, the weight was increased by 5-20 pounds, depending on individual 
performance.  Each set included 10 repetitions, followed by a 1-2 minute rest period.  
Completion of testing occurred once subjects were unable to perform 10 repetitions with correct 
form.  The prior 10-repetition amount was the subject’s 10 RM. 
 Prior to the end of the initial visit, subjects were given an information sheet that provided 
set guidelines for the 1-2 week period before the experimental session.  For the 2 days prior to 
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the experimental section, subjects were told to consume 8 cups (64 oz) of water and refrain from 
alcohol consumption and moderate levels of caffeine intake.  On the day before the experimental 
session, subjects underwent a 12-hour minimum fast.  On the day of the experimental section, 
subjects were instructed to consume 2 cups (16 oz) of water before their laboratory visit.  
Furthermore, subjects were also told to refrain from blood donation and exercise throughout the 
duration of the study.   
 
Experimental Session 
 
 The experimental session took place 1-2 weeks following the initial visit at the East 
Carolina Heart Institute.  This waiting period allowed subjects to recover from any possible 
soreness that may have occurred after the 10 RM testing.  The 10 RM testing was used for the 
resistance exercise bout in the experimental session in an effort to stimulate AMPK and the 
downstream signaling pathways.  A muscle biopsy was acquired prior exercise for pre-exercise 
measurements, immediately post-exercise (after completion of the final resistance exercise set 
and completion of preparation for biopsy), 1 hour following the immediately post-exercise 
biopsy, and two hours after taking the immediately post-exercise biopsy.  Muscle biopsy times 
are based upon the results of Drummond et al., which concluded that AMPK phosphorylaton is 
greater in old versus young men by 1-2 hours post-exercise (Drummond et al., 2008) (See Figure 
Below for experimental timeline).  Lastly, subjects were fasted for a minimum of 12 hours prior 
to this session.  
 
 
 
 
24 
Timeline of Experimental Session 
 
 
 
 
 
 
Figure 3.1.  Timeline of events for the experimental session for each subject.  Pre-Ex is the 
period preceding the exercise session.  0P is the exercise session.  1P is 60 minutes after the 
resistance exercise session.  2P is 120 minutes after the resistance exercise session.   
 
 
Acute Resistance Exercise 
 
 The acute resistance exercise was performed on a Cybex Leg Extension machine 
following the pre-exercise biopsy.  The subject began by performing a warm-up set consisting of 
10 repetitions performed at 50% of their predetermined 10 RM.  A 1-2 minute rest period was 
given between each set.  The subject then performed an additional warm-up set consisting of 5-7 
repetitions performed at 70% of their 10RM.  The final warm-up set consisted of 3-5 repetitions 
performed at 90% of their predetermined 10 RM.  The subject performed three working sets 
using their predetermined 10 RM.  Each set was performed until failure.  Once the subject 
reached failure, they completed 1-3 forced repetitions with the assistance of the investigator.  
This type of testing made an attempt to stimulate AMPK and downstream signaling pathways, 
such as apoptotic markers. 
 
Exercise 
 
Pre-Ex 
Pre-exercise 
biopsy 
0P 
immediately post-
exercise biopsy 
1P 
1-hour post biopsy 
2P 
2-hour post biopsy 
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Muscle Biopsies 
 
 All biopsy procedures were performed under sterile conditions.  First, a Povidone- 
Iodine swab stick was used to clean and disinfect the skin in the area where the biopsy took 
place.  It was then wiped off and an ethyl chloride medium stream spray was administered in 
order to numb the area where approximately 5 mL of 1% Lidocaine will be administered.  A 
small (about 1-2 cm) incision was made into the vastus lateralis of the left thigh with a No. 11 
surgical blade.  A 5-mm Bergstrom biopsy needle was inserted through the incision 2-3 
centimeters into the actual muscle.  A sterile procedure and proper suction was applied in order 
to minimize error and maximize biopsy size.   
Immediately following each biopsy, direct pressure and ice was applied to specific area to 
alleviate bleeding.  The wound was then dressed in an appropriate manner.  A plain white strip 
was placed directly over the wound; along with an average size band-aid on top of that.  A 
Tegaderm strip covered both of these.  This total bandage wasn’t removed until 1-2 days later.  It 
is semi-waterproof, but the subject was encouraged to cover with saran wrap when in the shower 
(Baths should be avoided).  A thick piece of gauze was then placed on top of that and was held in 
place by a wrap that goes around the entire thigh.  Athletic tap was wrapped on top of that (All 
the way around the thigh).  The gauze and tape portion were removed after a few hours.  This 
particular set-up allowed for proper healing and decreased the likelihood of scarring.   
There were a total of four biopsies throughout the course of this study.  Muscle biopsy 
times are based upon the results of Drummond et al., which concluded that AMPK 
phosphorylaton is greater in old versus young men by 1-2 hours post-exercise (Drummond et al., 
2008).  The first occurred prior to the acute resistance exercise session.  Subsequent biopsies 
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used alternating legs, with both the first and third biopsy being taken on the same side.  Once the 
pre-exercise biopsy was complete, the subject performed the acute resistance exercise session.  
Immediately post-exercise, the subject was moved to a bed and the second biopsy was taken.  
Preparation for this biopsy was completed in association with the first.  After 1 hour, the third 
biopsy was taken approximately 5 cm proximal to the first site.  The final biopsy was taken 2 
hours post-exercise approximately 5 cm proximal to the second biopsy site.  Biopsy samples 
were placed into a cryovial and flash frozen in liquid nitrogen for future western blot analyses.  
Samples were stored at a constant temperature of -80 degrees Celsius.   
 
Sample Analysis 
 
Analysis of Muscle Glycogen Content 
 Muscle glycogen content was analyzed by using a method modified from a variety of 
methods derived from Roy and Tarnopolsky (1998), Passonneau and Lowry (1993), and 
Passonneau and Lauderdale (1974).  An estimated amount of 5-15mg from each subject’s muscle 
sample was homogenized on ice in specified volumes of .1 M NaOH with a ground glass 
homogenizer.  An aliquot of each homogenate was heated for an estimated amount of 20 minutes 
at 80° C.  This attempted to destroy any free glucose.  In addition, the pH of each  
sample was neutralized with acetic acid and vortexing.  Furthermore, aliquots of each sample 
were placed in duplicate tubes of a sodium acetate buffer.   
 The following steps were performed in duplicate.  In an attempt to obtain free glucosyl 
units, glyogenolysis was accomplished.  Any remaining precipitate was centrifuged.  A glucose 
assay that is commercially available (based upon hexokinase and glucose-6-phosphate 
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dehydrogenase reactions; Sigma-Aldrich # GAHK20) was performed to determine free glucosyl 
units within each sample.  The glycogen content (µg/mg wet weight) of the muscle samples was 
then determined by comparison to a standard curve made with type III glycogen from rabbi liver 
(Sigma-Aldrich # G8876).  This was treated with the same approach as the muscle samples 
beginning with the NaOH step.   
 
Western Blotting Analysis for AMPK Phosphorylation, ACC, Procaspase-3, and Cleaved 
Caspase-3 Activity 
AMPK, ACC, protein contents, and phosphorylation, as well as total and cleaved 
caspase-3 protein contents were analyzed using the Western blot analysis method.  The following 
antibodies are commercially available: anti-AMPK [Cell Signaling Technology (CST); Danvers, 
MA; Cat. # 2532], anti-phospho-AMPK (CST; Cat. # 2535), anti-acetyl CoA Carboxylase 
(streptavidin-HRP, GE Life Sciences, RPN1231), anti-phospho-Acetyl CoA Carboxylase 
(Millipore Corporation; Temecula, CA; Cat. # 07-303; Lot#: LV1506382), anti-caspase-3, and 
anti-cleaved caspase-3 (CST).  Phospho-Acetyl CoA is an in vivo indicator of AMPK activity.  
A small portion of each frozen muscle biopsy sample was homogenized using a buffer that 
consists of 50 mM HEPES (pH 7.4), 0.1% Triton X-100, 4 mM EGTA, 10 mM EDTA, 15 mM 
Na4P2O7•10H2O, 100 mM ß-glycerophosphate, 25 mM NaF, 50 µg/ml leupeptin, 50 µg/ml 
pepstatin, and 33 µg/ml aprotinin.  All homogenizations were carried out in ice to prevent 
excessive heat build-up that can lead to protein denaturizing.  Furthermore, a ground glass 
homogenizer using a variable speed motor executed all homogenizations. 
Assessment of the homogenates for protein concentration was fulfilled in triplicate using  
alterations of the Lowry procedure (DC Protein Assay, Bio-Rad, Hercules, CA, USA).  Total 
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muscle protein homogenates were mixed in a loading buffer (50 mM Tris-HCl, pH 6.8, 10% 
glycerol, 2% SDS, 2% ß-mercaptoethanol, 0.1% bromophenol blue) at a dilution of 1 mg per ml.  
The mixture was then boiled for 5 minutes.  Proteins were separated by a 4-7.5% gradient 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  Gel electrophoresis 
occurred for 1.5 hours at 4˚C on a PVDF membrane at 100V in a transfer buffer.  The buffer 
contained 25 mM Tris-base pH~8.3, 192 mM glycine, and 20% methanol.  Ponceau S, stained 
the membranes.  Upon completion of staining, membranes were then dried and scanned into a 
digital image.  This image permits measurement of the relative total protein loaded into each 
label through the gray scale integrated optical density of the full length of each specific lane.  
Membranes were then blocked for one hour at room temperature in blocking buffer.  This buffer 
consisted of 5% nonfat dry milk in TBS-T (20 nM Tri-base, 150 mM NaCL, 0.1% Tween-20) 
pH 7.5.  The membranes were then incubated in the primary antibody diluted in 1% bovine 
serum albumin in TBS-T overnight at 4˚C.  Primary antibody dilutions consisted of anti-
phospho-AMPK:  1/4000; anti-AMPK:  1/1000; anti-phospho-ACC:  1/1000; anti-ACC:  1/1000; 
anti-procaspase-3:  1/1000; anti-cleaved caspase-3.   
Membranes then underwent 4 washing periods with 5 minutes between each wash in 
TBS-T, incubated in secondary antibody in blocking buffer for an hour at room temperature.  
Another round of 4 x 5 minutes wash periods in TBS-T followed.  Upon completion of the last 
wash, detection of the HRP activity occurred using a chemiluminescence reagent (Amersham, 
Piscataway, NJ) and exposure to autoradiographic film (Classic Blue Sensitive; Midwest 
Scientific, St Louis, MO, USA).  The integrated optical densities (IODs) were quantified by 
densitometry and calculation of the concentration of the antigen present in each muscle as the 
IOD was normalized to units of total muscle protein initially loaded on the gel.  Correction for 
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the grayscale IOD of each total lane was gauged on the image of the Ponceau stain that was 
formerly captured.  The HRP-conjugated anti-rabbit secondary antibody was obtained from 
Amersham. 
 
Statistics 
 
 An analysis of variance (ANOVA) with repeated measures was used to analyze the 
differences between and within groups over time for all western blot data.  Fisher’s LSD post-
hoc test for measurement of post-hoc differences was employed where necessary.  All 
correlations were performed with Pearson-Product-moment Correlation Analyses.  Subject 
characteristic data was analyzed using independent samples t-tests.  Significance was set at an 
alpha level of p < 0.05. 
 
 
 
 
 CHAPTER IV:  RESULTS 
 
Subject Strength and Work Volume 
 
 All 18 subjects completed both the initial and experimental session.  Total and relative 
volume of exercise was used to measure exercise performance for both the old and young age 
groups.  Total volume was determined by multiplying the total amount of weight lifted by the 
repetitions for each work set during the experimental session.  Additionally, total volume 
excluded all warm-up sets.  Relative volume was determined by taking the total volume divided 
by each individual’s fat-free mass (kg) (See Table 4.1 Below).      
 
Table 4.1.  Assessment of 10-repetition Maximum Strength and Workout Volume Between 
Young Adults (Y) and Old Adults (O). 
 
 Y (N=7) O (N=11) 
Estimated 10 RM (kg) 48 ± 10 32 ± 14 
 
Total volume (kg resistance x 
repetitions) 
1644.6 ± 195 1131.8 ± 395 
 
Relative volume (kg 
resistance/kg FFM) 
28 ± 1.9 19 ± 4.9 
 
No significant differences were found between groups for any measure.  Total volume (kg 
resistance) was calculated to assess the absolute amount of weight lifted during the working sets 
by each subject with the equation:  Total volume = [(resistance set 1(kg) x repetitions set 1) + 
(resistance set 2(kg) x repetitions set 2) + (resistance set 3(kg) x repetitions set 3)].  Total volume was 
normalized to fat free mass in order to show the relative amount of weight lifted:  relative 
volume = total volume (kg resistance) / fat free mass (kg).  All data are presented as means + 
SEMs. 
 
 
Cleaved Caspase-3 Western Blotting  
A significant main effect was observed for cleaved caspase-3 (elevated) and  
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cleaved/procaspase-3 ratio (elevated) for all post-exercise time points (0P, 1P, 2P) regardless of 
age (Figures 4.1 & 4.3).  No significant differences were observed for procaspase-3 (Figure 4.2).   
AMPK Western Blotting 
 A significant increase was found in AMPK phosphorylation at Thr172 at 0P when 
compared to PRE in old subjects, but this effect was not observed within the young group 
(Figure 4.4).  No difference was discovered in total AMPK between old and young subjects or at 
any time point (Figure 4.5).  Furthermore, a main effect of the phospho/total AMPK ratio was 
seen at 0P when compared to PRE for old and young subjects combined (Figure 4.6).     
ACC Western Blotting 
 Phospho-acetyl CoA (ACC) at Ser79 displayed a significant main effect at time 0P and 1P 
(elevated) when compared to PRE in old and young groups combined (Figure 4.7).  Similar main 
effect findings were consistent for total ACC (decreased at 0P and 1P) (Figure 4.8) and the 
phospho/total ACC ratio (increased at 0P and IP) (Figure 4.9). 
Muscle Glycogen Content 
 
 A significant difference was evident in glycogen content between old and young groups 
at the pre-exercise time point (PRE).  In addition, there was a significant effect of time points 
immediately post-exercise (0P), 1-hour post-exercise (1P), and 2-hours post-exercise (2P) for 
both old and young groups.  Furthermore, because there was a significant difference between age 
groups at PRE, but not post-exercise, it could be stated that the young group had a more 
pronounced drop in glycogen content following the acute resistance exercise in comparison to  
the old group (Figure 4.10).  Glycogen percent change from baseline showed a main effect  
difference between age groups across all time points (Figure 4.11).  
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Figure 4.1.  Mean ± SEM Cleaved Caspase-3 in young and old subjects and corresponding blots.  
PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour 
post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  *Significant main effect of 
time points 0P, 1P, and 2P vs. PRE regardless of age.   
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Figure 4.2.  Mean ± SEM Procaspase-3 in young and old subjects and corresponding blots.  
PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour 
post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  No significant differences 
were seen in procaspase-3 between old and young groups, or across any time points.   
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Figure 4.3.  Mean ± SEM in young and old subjects.  PRE is the pre-exercise biopsy, 0P is 
immediately post-exercise muscle biopsy, 1P is the 1-hour post-exercise muscle biopsy, 2P is the 
2-hour post-exercise biopsy.  *Significant main effect of time points 0P, 1P, and 2P vs. PRE 
regardless of age.   
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Figure 4.4.  Mean ± SEM phosphor-AMPK in young and old subjects and corresponding blots.  
PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour 
post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy. * Phospho-AMPK was 
significantly (p < 0.05) elevated above PRE in old subjects at the 0P time point. 
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Figure 4.5.  Mean ± SEM Total AMPK in young and old subjects and corresponding blots.  PRE 
is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour post-
exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  Total AMPK showed no 
significant differences between young and old groups, or across any time points. 
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Figure 4.6.  Mean ± SEM phospho/Total AMPK in young and old subjects and corresponding 
blots.  PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 
1-hour post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  * Phospho/total 
AMPK ratio showed a significant main effect of time point, for young and old groups combined 
at 0P vs. PRE.   
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Figure 4.7.  Mean ± SEM phosphor-ACC in young and old subjects and corresponding blots.  
PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour 
post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  * Significant (p < 0.05) main 
effect of time points, and post-hoc analysis showed that time points 0P and 1P were elevated vs. 
PRE for young and old groups combined. 
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Figure 4.8.  Mean ± SEM Total ACC in young and old subjects and corresponding blots.  PRE is 
the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour post-
exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy. *Significant (p < 0.05) main effect 
of time points, and post-hoc analysis showed that time points 0P and 1P were decreased vs. PRE 
for young and old groups combined. 
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Figure 4.9.  Mean ± SEM phospho/Total ACC in young and old subjects and corresponding 
blots.  PRE is the pre-exercise biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 
1-hour post-exercise muscle biopsy, 2P is the 2-hour post-exercise biopsy.  *Significant (p < 
0.05) main effect of time points, and post-hoc analysis showed that time points at 0P and 1P 
were elevated vs. PRE for young and old groups combined.   
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Figure 4.10.  Mean ± SEM glycogen content in young and old subjects.  PRE is the pre-exercise 
biopsy, 0P is immediately post-exercise muscle biopsy, 1P is the 1-hour post-exercise muscle 
biopsy, 2P is the 2-hour post-exercise biopsy. †Significant (p < 0.05) difference between young 
and old groups at PRE time point.  *Significantly lower than PRE within young and old groups 
independently. 
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Figure 4.11.  Mean ± SEM glycogen content in young and old subjects.  0P is immediately post-
exercise muscle biopsy, 1P is the 1-hour post-exercise muscle biopsy, 2P is the 2-hour post-
exercise biopsy.  *Main effect difference between age groups versus PRE across all time points.  
 
 
  
 
 
43 
Association of AMPK Activity and Cleaved Caspase-3 with Glycogen Content 
We found a significant, or close to significant, relationship between glycogen content and 
the phospho/total ACC ratio at time points PRE, 0P, 1P, but not 2P, regardless of age (Figs 4.12-
4.15).  In addition, we chose to further examine the relationship of glycogen content with ACC 
phosphorylation status as opposed to AMPK phosphorylation because it is a better indicator of 
AMPK activity (Park et al., 2002).  Increased muscle glycogen content was also associated with 
a lower phospho/total ACC ratio.  Furthermore, no significant correlation between AMPK 
activity and cleaved caspase-3 was observed.  
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Figure 4.12.  Relationship between glycogen content and the phospho/total ACC ratio (top) and 
between AMPK activity and cleaved caspase-3 (bottom) at the pre-exercise time point.  
Significance is set at p < 0.05. 
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Figure 4.13.  Relationship between glycogen content and the phospho/total ACC ratio (top) and 
between AMPK activity and cleaved caspase-3 (bottom) at the immediately post-exercise time 
point.  Significance is set at p < 0.05. 
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Figure 4.14.  Relationship between glycogen content and the phospho/total ACC ratio (top) and 
between AMPK activity and cleaved caspase-3 (bottom) at the one-hour post-exercise time point.  
Significance is set at p < 0.05. 
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Figure 4.15.  Relationship between glycogen content and the phospho/total ACC ratio (top) and 
between AMPK activity and cleaved caspase-3 (bottom) at the two-hour post-exercise time point.  
Significance is set at p < 0.05.  
 
  
 CHAPTER V:  DISCUSSION 
 
 
The purpose of this study was to examine the response of cleaved (activated) caspase-3 to 
acute resistance exercise in the skeletal muscles of young versus old subjects.  It was 
hypothesized that skeletal muscle cleaved caspase-3 content would increase in response to acute 
resistance exercise.  It was further hypothesized that skeletal muscle cleaved caspase-3 content 
would be higher after acute resistance exercise in older versus younger individuals.  
Cleaved caspase-3 and cleaved/procaspase-3 ratio showed a significant main effect 
(elevated) at all post exercise time points (0P, 1P, & 2P) in response to acute resistance exercise 
regardless of age.  Similar results were observed in an investigation by Yang, Jemiolo, and 
Trappe, which showed an acute increase in procaspase-3 mRNA expression following resistance 
exercise (Yang, Jemiolo, & Trappe, 2006).  Again, most previous literature refers to the 32kD 
form of caspase-3 as caspase-3 or total caspase-3; however, for the purposes of this document, it 
is referred to as procaspase-3.  In addition, the 19kD or activated form of caspase-3 is referred to 
as cleaved caspase-3.  An investigation by Kocturk et al. found significant increases in cleaved 
caspase-3 activity in response to aerobic exercise in young rats.  More specifically, increases in 
cleaved caspase-3 were observed at all post-exercise time points (Kocturk et al., 2007).  Kocturk 
et al. found that cleaved caspase-3 activity at 3-hours post-exercise was the most elevated when 
compared to control (Kocturk et al., 2007).   Therefore, cleaved caspase-3 responses to acute 
resistance exercise may be more prevalent at later time points than were examined within this 
investigation.  Moreover, there was more cleaved caspase-3 activity within the soleus muscle in 
comparison to the gastrocnemius (Kocturk et al., 2007).  Within the present investigation, fast-
twitch fibers were mixed via homogenization of muscle biopsy samples with slow-twitch fibers.  
Sarcopenia and diminished muscle hypertrophy occur in fast-twitch muscle fibers; however, this 
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is unseen among slow-twitch fibers (Rogers & Evans, 1993). On the contrary, an investigation 
by Quadrilatero et al., found that a prolonged moderate intensity aerobic exercise does not alter 
procaspase-3 activity (Quadrilatero et al., 2009).  The current investigation also displayed an 
increase in cleaved caspase-3 at both PRE and 0P in the old when compared to the young group; 
however, these values failed to reach significance.  To our knowledge this is the first study 
investigating cleaved caspase-3 acute response to resistance exercise.  Procaspase-3 showed no 
significant difference in response to resistance exercise or between old and young groups across 
time points in this present investigation. 
In agreement with the hypothesis, AMPK phosphorylation at Thr172 was elevated in old  
subjects immediately post-resistance exercise (0P).  This response was not present among the 
young.  In addition, there was a significant main effect in the phospho/total AMPK ratio 
immediately post-resistance exercise in both old and young groups; however, no differences 
between age groups alone were evident.  No differences between old and young groups at any 
time point in phospho-acetyl CoA carboxylase (ACC) were observed.  ACC is a downstream 
marker of AMPK activity (Hawley et al., 1996).  In contrast to phospho-AMPK, there was a 
significant increase (main effect) in phospho-ACC and phospho/total ACC at 0P and 1P (1-hour 
post-exercise) for both old and young groups compared to pre-exercise levels (PRE).  No 
significant effect of age groups for phospho/total ACC ratio were observed at any time point.  
 Current results concerning AMPK phosphorylation partially agree with previously 
published literature.  Research conducted by Drummond et al. displayed a significant increase 
from baseline in AMPK phosphorylation in older subjects, but not in younger, at both 1 and 3 
hours post-resistance exercise (Drummond et al., 2008).  The results concluded by this 
investigation illustrated a significant elevation of AMPK phosphorylation in old subjects 0P; 
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however, the phosphorylation of AMPK fell to levels comparable to young subjects by 1P.  More 
specifically, phosphorylation of AMPK approached baseline in old and returned to baseline in 
young by 1P.  On the contrary, Drummond et al. found phospho-AMPK levels to remain 
elevated for up to 3-hours post-exercise.  Factors contributing to these dissimilarities could 
include the fact that Drummond et al. used 8 sets of 10 repetitions at 70% of a 1 repetition 
maximum, while this investigation used only 3 working sets at 100% of a 10-repetition 
maximum.  Even though the present investigation went until failure, the extra working sets 
utilized within the Drummond et al. investigation may have contributed to higher and prolonged 
phosphorylation of AMPK in response to leg extension exercise (Drummond et al., 2008).  An 
investigation by Thomson and Gordon concurred with this likelihood.  Thomson and Gordon 
found that phosphorylation of AMPK is higher in old versus young muscle both a rest and after 
chronic overload in rats (Thomson & Gordon, 2005).  Furthermore, the Drummond investigation 
required subjects to ingest an amino acid and carbohydrate supplement (leucine-enriched EAA) 
in addition to the resistance exercise.  The use of non-fasted subjects by Drummond et al. may 
have had an impact of phosphorylation of AMPK, since AMPK plays a role in internal energy 
stores and creating homeostasis.  The current investigation was conducted with the use of fasted 
subjects.   
 The present investigation found an age-related difference in the phosphorylation of 
AMPK in response to resistance exercise; however, ACC phosphorylation, an indicator of 
AMPK activity, was similar between both the old and young groups.  More specifically, ACC 
phosphorylation was elevated equally in both old and young groups and in a more sustained 
manner when compared to AMPK phosphorylation.  ACC phosphorylation and phospho/total 
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ACC ratio displayed a significant main effect at 0P and 1P in comparison to the PRE values in 
old and young age groups combined.  These data further conclude that AMPK activation may not  
have differed between the groups.   
 Many factors could have been contributors to the lack of differences observed in the  
phospho-ACC between the old and young groups within the present investigation.  One such 
factor to why significant differences may not have been observed could be due to the possibility 
that the older adults were healthier than the average older adult.  Therefore, the group of old 
subjects within this study may not have been truly representative of the general older adult 
population.  The invasiveness of the present investigation may have also had an effect on the 
willingness to participant.  Therefore, an N of only 18 was used for the duration of the study.  
The delimitations of this study omitted all individuals that participated in regular physical 
activity.  Consequently, the young group may not abide by the same lifestyle factors as the older 
subjects; therefore, the older group may simply be healthier than the young group.  Another 
aspect to consider is the fact that the differences seen in phospho-ACC between the old and 
young group may have only occurred in the fast-twitch fibers.  These fibers were mixed via 
homogenization of muscle biopsy samples with slow-twitch fibers in the current study.  
According to Thomson and Gordon, the utmost AMPK and ACC results occur only in fast-
twitch muscle fibers and not slow-twitch (Thomson & Gordon, 2008).  Homogenization 
processes leading to the mixing of fiber types could also be a contributor to the dearth of 
noticeable differences between phospho-ACC among the age groups.  
Our results failed to show a definitive relationship between AMPK and cleaved caspase-3 
activation before or after acute resistance exercise within young and old skeletal muscle; 
however, other investigations have shown that activation of AMPK (by AICAR or other 
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common activator) leads to increases in caspase-3 activity within other cell types (Sai et al., 
2006; Riboulet-Chavey et al., 2008; Jung et al., 2010).  Investigations have shown that inhibition 
of AMPK activation can suppress both total and cleaved caspase-3 activity in cancer cells (Kim 
et al., 2009; Mukherjee et al., 2008; Khanal et al, 2011).  A study by Riboulet-Chavey et al. 
found a fourfold increase in cleaved-caspase-3 after a period of incubation with an AMPK 
activator within pancreatic β-cells (Riboulet-Chavey et al., 2008).  In contrast, investigations by 
Konishi et al. & Yeh et al. found that AMPK was anti-apoptotic and was associated with 
cardiovascular protection in cardiac myocytes (Konishi et al., 2011 & Yeh et al., 2010).  More 
specifically, the AMPK inhibitor dorsomorphin induced apoptosis via increased caspase-3 
activity (Konishi et al., 2011).  An investigation by Nakashima and Yakabe found that AICAR-
induced activation of AMPK failed to induce mRNA expression of caspase-3 within C2C12 
myotubes (Nakashima & Yakabe, 2007).  AMPK may provide increased protection against 
apoptosis in multinucleated myotubes in comparison to single-nucleated myoblasts (Niesler, 
Myburgh, & Moore, 2007).  As previously stated, fast-twitch fibers were concealed via 
homogenization of muscle biopsy samples with slow-twitch fibers.  Moreover, sarcopenia 
predominately affects these fast-twitch muscle fibers; (Rogers & Evans, 1993).  These 
investigations are in contrast to our pilot data, which found increased procaspase-3 protein 
expression in response to 1 week of AMPK activation in whole muscle of rats.  Regardless of 
whether AMPK induces procaspase-3 protein or mRNA expression in skeletal muscle, the results 
of the current investigation indicate that AMPK activation may not lead to increased cleaved 
caspase-3 in response to resistance exercise within aged human skeletal muscle.  
 Investigations have shown that AMPK also has the ability to sense cellular energy 
reserves in the form of glycogen.  Therefore, glycogen content is known to affect AMPK activity 
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by increased phosphorylation.  Glycogen content may also affect AMPK activity independently 
(McBride et al., 2009).  It is to our knowledge that glycogen content before and after acute 
resistance exercise in old versus young subjects has not been formerly investigated.  The current 
investigation observed a significant difference in glycogen content between both age groups at 
PRE.  This illustration is supported by previous data, which displayed a decrease in resting 
muscle glycogen levels with increasing age (Cartee, 1994).  The present study exhibited a 
significant post-exercise decrease for both age groups.  This data is also consistent with previous 
literature.  Tesch, Colliander, & Kaiser showed a significant decrease in muscle glycogen content 
following a variety of resistance exercises in young subjects (Tesch, Colliander, & Kaiser, 1986). 
  Within the present investigation, glycogen content declined more in young than in old 
subjects following acute resistance exercise and was statistically equal at 0P, 1P, and 2P.  One 
potential explanation for these variances in glycogen depletion may be a result of the different 
skeletal muscle fiber types found in old and young adults.  Sarcopenia is specific to losses in 
fast-twitch muscle fibers as opposed to slow-twitch (Rogers & Evans, 1993).  Therefore, the 
elderly have a lower percentage of fast-twitch fibers when compared to younger individuals 
(Anderson, 2003).  Fast-twitch muscle fibers are required for quick and powerful movements; 
therefore, they store and use more glycogen.  In addition, this utilization of more glycogen may 
be associated to a more intense depletion in overall glycogen content from PRE to 0P in young 
subjects.  The analogous glycogen content observed in the present investigation may have had a 
significant main effect on ACC phosphorylation and thus AMPK activity.  This in turn may have 
generated an analogous ACC phosphorylation in both old and young groups.  There was a 
significant negative correlation between glycogen content and ACC phosphorylation status at 1P.  
There was also a negative correlation between glycogen content and ACC phosphorylation at 
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both 0P, and 1P that approached significance.  No significant correlation between AMPK 
activity and cleaved caspase-3 was observed.                     
 The control of procaspase-3 activity is a multifaceted process and encompasses several  
interconnected signaling pathways and cascades.  Investigations have shown that procaspase-3 is 
activated by the initiator caspase-9 and is responsible for fulfilling the final executional 
processes of apoptosis (Siu et al., 2009).  In addition, AMPK’s involvement in nuclear apoptosis 
within skeletal muscle still needs further investigation.  In contrast, the present investigation does 
provide relevance for future research efforts.  There were no significant differences between age 
groups displayed in ACC, cleaved caspase-3, and procaspase-3.  However, although no 
significant differences were seen between age groups, there was slightly higher cleaved caspase-
3 content in the skeletal muscle of old at time points 0P and 1P.  Furthermore, it may be 
advantageous to separate the muscle sample by fiber type (fast-twitch versus slow-twitch) to 
analyze nuclear apoptosis changes on the specific fiber types of old and young groups.     
 In summary, the current investigation examined cleaved caspase-3 response to acute 
resistance exercise and its relation to muscle glycogen content and AMPK activation in old 
versus young subjects.  AMPK phosphorylation was increased among the old subjects, but not in 
young, immediately following resistance exercise.  Additionally, glycogen content was 
significantly lower in old subjects in comparison to young at time point PRE.  In both age 
groups, glycogen content decreased and remained in a depleted state for time points 0P, 1P, and 
2P.  Cleaved caspase-3 was elevated at all post-exercise time points (0P, 1P, 2P) regardless of 
age.  Therefore, these data suggest a robust response of cleaved caspase-3 (e.g. caspase-3 
activity) in response to acute resistance exercise in both young and old subjects.  However, 
exercise-induced AMPK activation may not be the mechanism by which this occurs.  Regardless, 
 
 
55 
future research is necessary in order to fully conclude whether older adults with an increased 
progression of sarcopenia show dissimilar results pertaining to the relationship between glycogen 
content and AMPK phosphorylation, ACC, and other markers of apoptosis.   
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APPENDIX B: INFORMED CONSENT DOCUMENT 
 
Principal Investigator:  Scott E. Gordon, Ph.D. 
Institution:  Human Performance Laboratory 
Address:  363 Ward Sports Medicine Building 
Telephone #:  (252) 737-2879 
 
This consent form may contain words that I do not understand.  I should ask the study doctor or the study 
coordinator to explain any words or information in this consent form that I do not understand. 
 
INTRODUCTION 
 
I have been asked to participate in a research study being conducted by Scott E. Gordon, Ph.D. and his associates.  
This research is designed to determine the response of several molecules in muscle after one resistance exercise 
(strength training) session, and if this response changes with age.  All of these molecules and cells are involved with 
muscle hypertrophy (growth). 
 
We will study 10 younger (18-45 years) and 20 older inactive adults (46-85 years), at rest and 
during and after a resistance exercise session for the legs.  Inactive is defined as not having 
participated in any regular form of exercise for the past six months (less than 30 minutes per day, 
one day per week).  Studies will take place in the Human Performance Laboratory and Brody 
School of Medicine at East Carolina University. 
 
PLAN AND PROCEDURES 
 
Prior to any testing, I will report to the Human Performance Laboratory Fitness, Instruction, 
Testing, and Training (FITT) Building to first be allowed to read and sign this Informed Consent 
for research as then fill out a medical history questionnaire and 3-day food record. I will be 
allowed to complete this process on the day of my first visit. On this day, I will then undergo 
determination of my height and body weight, and percent body fat.  I will also undergo strength 
testing and familiarization with the resistance exercise test.  One to two weeks later, I will report 
to the East Carolina Heart Institute Room 2379 in a fasted state for the resistance exercise testing 
session, four blood samples from a forearm vein, and 4 biopsies of the thigh muscles. 
 
The following section is an outline of the experimental visits and the procedures to be 
accomplished on each visit.  Note that more detailed descriptions of each procedure 
immediately follow this section.  There will be 2 visits for a total of approximately 5 hours 
of total participation time spread over approximately 2 weeks: 
 
First Visit (Human Performance Lab FITT Building) (1.5 hours): 
1.) Thorough interview in person for informed consent, health history questionnaire, and 3-
day food record. 
2.) Determination of height, weight, and skinfold thickness (fat pinch) for percent body fat. 
3.) Determination of the maximum weight I can lift 10 times (10 repetition maximum, also 
called a 10 RM) for the seated leg extension exercise. 
4.) Counseling on food choices for those individuals undergoing the high carbohydrate diet, 
and instructions for keeping dietary logs. 
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Second Visit (East Carolina Heart Institute Room 2379) (7-14 days after initial visit) (3.5 hours): 
1.) I will report to the East Carolina Heart Institute Room 2379, in the morning after an 
overnight fast (not having eaten after midnight the night before). 
2.) Four small blood samples will be obtained during this visit from a forearm vein (before, 
and after exercise). 
3.) Four thigh muscle biopsies (tissue samples) will be performed during this session, two on 
each leg. 
4.) A resistance exercise (strength training leg extension) bout of approximately 15 minutes 
focused on the thigh muscle group will be performed. The bout will consist of 6 sets of 
leg extension exercise.  
 
Detailed Description of the Procedures to be Used During this Study: 
• Body composition screening.  My height and weight will be measured on my first visit.  
My body fat will be estimated by measuring skinfold thicknesses (fat pinch) with a 
skinfold caliper at four sites:  biceps, triceps, back, and waist.  I may feel a slight pinch or 
squeeze from the caliper at the skinfold sites, but no known risks are associated with this 
procedure. 
• Strength testing.  An exercise test to determine my strength levels and familiarize me 
with the resistance exercise protocol will be performed during my first visit (after the 
informed consent).  As part of my familiarization and subject characterization, I will be 
assessed for maximal strength by 10-repetition maximum (10-RM) testing.  This will 
entail determining the maximum amount of weight that I can lift in ten repetitions for the 
leg extension exercise.  This procedure will consist of me initially lifting lighter weights 
and progressing to the heaviest weight that I can lift.  An adequate amount of rest will be 
provided between repetition attempts.  All exercises will be performed on Cybex weight 
machines.  This session will also serve as a familiarization session to make me 
comfortable with the resistance exercise to be performed during the experimental session.  
I will be examined for proper exercise technique during this session and instructions or 
modifications will be provided if necessary.  During this session, my tolerance for the 
heavy resistance exercise protocol will also be assessed. 
• High Carbohydrate Diet.  If I am one of the older subjects that is randomly selected to do 
the high carbohydrate diet, I will be instructed to eat a diet high in carbohydrates for the 3 
days prior to my second visit to the laboratory.  I will be counseled on food choices and 
given food guidelines to assist with dietary choices during the initial visit.  The goal is for 
me to eat approximately 65-70% of my total calories from carbohydrates while 
attempting to decrease my calories from fat accordingly (protein intake will remain 
unaltered).  Some examples of high CHO food choices that are low fat but not low in 
protein are most vegetables, very lean meats, skim (non-fat) milk, etc.  Dr. Kimberly B. 
Heidal, PhD, MHS, RD, LDN, from the ECU Dept. of Nutrition is a team member for 
this study and has provided guidelines and dietary instructions to help accomplish this 
goal.  There is no anticipated risk to me while I undergo this level of carbohydrate 
consumption for 3 days.   
• Leg resistance exercise workout.  During my second visit to the laboratory, I will perform 
a 15-minute resistance exercise bout focused on the quadriceps (thigh) muscle group.  
The bout will consist of 6 sets of leg extension exercise.  The first 3 sets will be warm-up 
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sets performed at 50% (8 repetitions), 70% (6 repetitions), and 90% (4 repetitions) of my 
previously determined 10-RM weight. The fourth through sixth sets will be performed at 
100% of the 10 RM weight and will be performed until I am no longer able to perform 
them on my own (approximately 10 repetitions).  I will rest for 90 seconds between all 
sets 
• Fasting blood draws.  I will not have anything to eat 12 hours prior to my second visit to 
the lab so that blood can be drawn from my forearm vein by a needle. During the second 
visit to the lab, blood will be drawn before, and after the resistance exercise workout 
described above.  Four total blood samples of 5 milliliters each will be obtained during 
this study.  The total amount of blood obtained will be 20 milliliters, which is 
approximately 1/25 of a pint. 
• Muscle Biopsies.  I will undergo four muscle biopsies (tissue samples) to determine the 
levels of several molecules in muscle after one resistance exercise (strength training) 
bout.  These biopsies will be obtained immediately before, immediately after, and 1 and 
2 hours after the resistance exercise bout in visit # 2.  For this procedure, I will have a 
small amount of anesthesia (3 cc of 1% Lidocaine) injected in a ½ inch area under the 
skin of my thigh.  A small (1/4 inch) incision will then be made through the skin, fat and 
fibrous tissue that lies over the muscle.  A biopsy needle (about ½ the width of a pencil) 
will then be inserted ½ to 1 inch into the muscle.  A small piece of muscle (½ the size of 
an eraser on the end of a pencil) will then be clipped out with the biopsy needle.  The 
needle will be withdrawn and the muscle sample immediately preserved by freezing.  Dr. 
Robert Hickner, Ph.D. or Dr. Timothy Gavin, Ph.D. will perform the muscle biopsies.  
These investigators have performed a total of over 500 muscle biopsies. 
 
POTENTIAL RISKS AND DISCOMFORTS  
 
There are certain risks and discomforts that may be associated with this research, including those 
listed below. 
• The general performance of muscular exercise and physical effort can entail the potential 
hazards of injury from overexertion and/or accident.  The possibility of cardiopulmonary 
(heart and lung) overexertion is slight.  It will be minimized by screening, selection, and 
monitoring procedures which are designed to anticipate and exclude the rare individual 
for whom exercise might be harmful.  It is questionable whether it is possible to overexert 
the heart by voluntary physical effort unless there is some underlying disease.  
Nevertheless, there are a number of disorders, some of which can readily escape clinical 
detection, where strenuous exercise may be potentially hazardous or may cause disability.  
Some of these, such as aneurysms (blood vessel ruptures) in the brain, solitary pulmonary 
cysts (small sacs of fluid in the lung), or alveolar blebs (small lung lesions), are rare and 
not readily diagnosed in the absence of symptoms.  For these disorders, a history of 
tolerance to prior physical effort must suffice.  For other, more common conditions such 
as ischemic heart disease (low blood and oxygen flow to the heart), several risk factors 
can be identified through the preliminary medical history and physician screening 
process. 
• The risks specifically associated with resistance exercise are very low, and this study will 
be planned to avoid injury to the musculoskeletal (muscle and bone) system.  Possible 
risks include the possibility of strains or pulls of the involved muscles, delayed muscle 
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soreness 24 to 48 hours after exercise, muscle spasms (cramping), and, in extremely rare 
instances, muscle tears.  Such risks are very low.  Dizziness and fainting may also occur 
infrequently.  I understand that every effort will be made by the researchers to make this 
investigation safe for my participation through proper instruction of the techniques and 
proper warm-up prior to exercise and testing.  Furthermore, risks will be reduced by close 
supervision by experienced personnel to ensure that I utilize proper form. 
• The total amount of blood drawn (1/25 of a pint) is negligible. There is an extremely 
small risk of local hematoma (bruising) or infection associated with insertion of 
venipuncture needles.  In obtaining blood samples from a vein with a needle, the risks to 
me are of local discomfort, syncope (faintness), and hematomas (bruising).  Thrombosis 
(blood clot in the vein), embolism (a blood clot that has come loose and may lodge itself 
in an artery), and infections are potential risks but are of very rare occurrence.  Risks will 
be reduced or eliminated by having investigators who are trained and proficient in 
phlebotomy (puncturing veins with needles) use aseptic techniques.  Furthermore, I will 
be in a seated position while blood is being obtained.  All blood samples will be drawn in 
the laboratory under aseptic conditions with biohazard protection for the investigators 
and myself. 
• Robert Hickner, Ph.D. or Dr. Timothy Gavin, Ph.D. will perform all biopsies, and Dr. 
Walter Pofahl, M.D. will provide medical coverage for biopsies performed in this 
investigation.  There is a small risk of hematoma (bruising) or infection around the 
biopsy site, as well as muscle cramping, mild muscle tenderness and occasional bruising.  
The risk will be minimized by using sterile procedures and applying pressure to the 
biopsy site for 10 minutes, or until bleeding has stopped if longer than 10 minutes.  A 
steri-strip (bandage) will be applied over the incision and will remain in place for at least 
4 days to close the incision during healing.  A pressure wrap will be placed around the 
biopsied thigh and will remain in place for 8 hours following the biopsy.  There is an 
extremely remote risk of allergic reaction to the Lidocaine anesthesia.  This risk will be 
minimized by using subject’s who have had prior exposure to Lidocaine or Novocaine 
anesthesia.  This precaution should eliminate this risk.   
• The procedures and circumstances encompassed by this protocol provide for a high 
degree of safety.  Every attempt will be made by the investigators to minimize any risks 
of this study to me.  This includes familiarization, technique instruction and practice, 
supervision by experienced personnel, screening, and individualized testing and 
monitoring.  The investigators will employ a close interaction with the physician in their 
clinical unit during this study.  My safety will be enhanced in this study with 
individualized supervision during all laboratory visits.  I will be asked to immediately 
alert a member of the research team if I have any injury or health problem.  These factors 
should dramatically contribute to a reduction, if not an elimination, of any potential risks 
associated with this study. 
• There is the potential risk that the results, especially if unfavorable or difficult to 
understand, may lead to my anxiety.  However, I understand that the investigators are 
available to answer any of my questions or concerns regarding such matters, even after 
termination of the study. 
• To my knowledge, I am not allergic to “caine-type” anesthetics. For example, I have 
not had an allergic reaction to an injection at the dentist’s office. To my knowledge, 
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I do not possess any condition which would result in excessive bleeding and I do not 
have known heart disease, i.e., had a heart attack. 
• I am aware that there are unforeseen risks involved with this and all research studies. 
 
POTENTIAL BENEFITS 
 
There are potential benefits to society.  The results of this study will help to determine the response of several 
muscle growth-related molecules and cell types in muscle after one resistance exercise (strength training) session, 
and if this response changes with age.  The benefits of this study far outweigh the risks. 
There are potential benefits to subjects.  I will gain information about my blood sugar (glucose) and insulin levels, which may be indicators of 
health status due to the importance of blood glucose regulation.  These blood glucose and insulin values will be available to me at any time if I 
request them.  Furthermore, if my blood glucose and insulin values fall outside of the normal clinical range, I will be contacted by the 
investigators and advised to consult my personal physician.  I will obtain information about my percent body fat and body mass index (BMI, or 
weight/height squared), which is also an important indicator of risk for metabolic diseases such as diabetes or heart disease.  I will also gain 
information on my muscle fiber type (slow-twitch or fast-twitch), which is important component of athletic ability characteristics. 
 
I will be paid a total of $200.00 compensation upon completion of the entire study. 
 
SUBJECT PRIVACY AND CONFIDENTIALITY OF RECORDS 
 
Only the investigators associated with this study will have access to the data obtained.  The 
identity of the subjects will be protected by numeric coding.  The data will be stored in the office 
of the Principal Investigator, or in a locked storage room. No identifying information will be 
released. 
 
TERMINATION OF PARTICIPATION 
 
My participation in this research study may be terminated without my consent if the investigators 
believe that these procedures will pose unnecessary risk to myself.  I may also be terminated 
from participation if I do not adhere to the study protocol. 
 
COST AND COMPENSATION 
 
I will be paid $50.00 for my time and inconvenience for each muscle biopsy for a maximum of 
$200 for completion of the entire study. There are no costs to me for participation in this study. 
 
The policy of East Carolina University does not provide for 
compensation or medical treatment for subjects because of physical or 
other injury resulting from this research activity.  However, every effort 
will be made to make the facilities of the School of Medicine available 
for treatment in the event of such physical injury. 
 
VOLUNTARY PARTICIPATION 
 
I understand that my participation in this study is voluntary.  Refusal to participate will involve no penalty or loss of benefits to which I am 
otherwise entitled.  Furthermore, I may stop participating at any time I choose without penalty, loss of benefits, or without jeopardizing my 
continuing medical care at this institution. 
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RESEARCH PARTICIPANT AUTHORIZATION TO USE AND DISCLOSE 
PROTECTED HEALTH INFORMATION 
 
The purpose of the information to be gathered for this research study is to better understand the 
response of several molecules in muscle after one resistance exercise (strength training) session, 
and if this response changes with age.  The individuals who will use or disclose my identifiable 
health information for research purposes include Dr. Scott Gordon, Dr. Timothy Gavin, Dr. 
Robert Hickner, Dr. Walter Pofahl, and Mr. Bradley Harper.  Individuals who will receive my 
identifiable health information for research purposes also include Dr. Scott Gordon, Dr. Timothy 
Gavin, Dr. Robert Hickner, Dr. Walter Pofahl, and Mr. Bradley Harper.  The type of information 
accessed for this research study includes 1) general medical history (including family health 
history, medications, nutrition, physical activity levels and body weight history), 2) body 
composition information, blood levels of insulin, glucose, and other compounds related to 
muscle hypertrophy and metabolism, and 3) muscle fiber type percentage as well as growth-
related molecules in my thigh muscle.  The information will be used and disclosed in such a way 
as to protect my identity as much as possible; however, confidentiality cannot be absolutely 
guaranteed.  Someone receiving information collected under this Authorization could potentially 
re-disclose it, and therefore it would no longer be protected under the HIPAA privacy rules 
(federal rules that govern the use and disclosure of my health information).  There is not an 
expiration date for this Authorization. 
 
I may not participate in this study if I do not sign this Authorization form.  I may revoke 
(withdraw) this Authorization by submitting a request in writing to Dr. Scott Gordon.  However, 
the research team will be able to use any and all of the information collected prior to my request 
to withdraw my Authorization.   
 
To authorize the use and disclosure of my health information for this study in the way that has 
been described in this form, I must sign below and date when I signed this form.  A signed copy 
of this Authorization will be given to me for my records. 
 
________________________________________________________________________ 
Participant’s Name (print)                              Signature                                        Date  
 
________________________________________________________________________ 
Authorized Representative Name (print)-----Relationship        Signature             Date  
 
________________________________________________________________________ 
Person Obtaining Authorization                     Signature                                         Date  
 
If I have questions related to the sharing of information, I am advised to call Scott Gordon at 
252-737-2879.  I may also telephone the University and Medical Center Institutional Review 
Board at 252-744-2914.  In addition, if I have concerns about confidentiality and privacy rights, I 
may phone the Privacy Officer at Pitt County Memorial Hospital at 252-847-6545 or at East 
Carolina University at 252-744-2030. 
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PERSONS TO CONTACT WITH QUESTIONS 
 
The investigators will be available to answer any questions concerning this research, now or in 
the future.  I may contact the primary investigators Scott E. Gordon, Ph.D. at 252-737-2879 
(weekdays) or 252-321-7655 (nights and weekends).  Also, if questions arise about my rights as 
a research subject, I may contact the Chairman of the University and Medical Center Institutional 
Review Board at phone number 252-744-2914 (weekdays).  
 
CONSENT TO PARTICIPATE 
 
I certify that I have read all of the above, asked questions and received answers concerning areas 
I did not understand, and have received satisfactory answers to these questions. I willingly give 
my consent for participation in this research study.  (A copy of this consent form will be given to 
the person signing as the subject or as the subject’s authorized representative.) 
 
_____________________________________________________________ 
Participant’s Name (Print) 
 
_____________________________________________________________ 
Signature of Participant    Date  Time 
 
WITNESS:  I confirm that the contents of this consent document were orally presented, the 
participant or guardian indicates all questions have been answered to his or her satisfaction, and 
the participant or guardian has signed the document.  
 
 
_____________________________________________________________ 
Witness’s Name (Print) 
 
_____________________________________________________________ 
Signature of Witness      Date   
 
 
PERSON ADMINISTERING CONSENT:  I have conducted the consent process and orally 
reviewed the contents of the consent document. I believe the participant understands the 
research. 
 
_____________________________________________________________ 
Person Obtaining Consent (Print) 
 
_____________________________________________________________ 
Signature of Person Obtaining Consent        Date 
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_____________________________________________________________ 
Principal Investigator’s Name (Print) 
 
_____________________________________________________________ 
Signature of Principal Investigator          Date 
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FUTURE TESTING OF BLOOD/MUSCLE SAMPLES 
 
Upon termination of this study, the blood and muscle samples collected for this study will be 
stored for up to 7 years to research scientific questions specifically related to age-related changes 
in molecules regulating muscle mass in response to resistance exercise.  I understand that I have 
the right to decline consent for this storage beyond termination of the present study, and that this 
declination of consent would not exclude me from participation in the present study.  I will 
continue to be the owner of the samples and retain the right to have the sample material 
destroyed at any time during this study by contacting the study principal investigator Scott 
Gordon, Ph.D. at 252-737-2879.  During this study, the samples will be stored with number 
identifiers only; however, the number identifier will be linked to a specific name and will be 
kept on file in the possession of the principal investigator.  The linked file will be stored 
password protected on the Principal Investigator’s computer with CD backup.  No other 
individuals will have access to these identifying materials unless the principal investigator is 
required by law to provide such identifying information.  Data will not be publicly available and 
participants will not be identified or linked to the samples in publication.  If a commercial 
product is developed from this research project, I will not profit financially from such a product.  
Furthermore, there are no plans for me to profit financially from such a product.   
 
 
CONSENT TO PARTICIPATE IN FUTURE TESTING OF 
BLOOD/MUSCLE SAMPLES  
 
I certify that I have read all of the above, asked questions and received answers concerning areas 
I did not understand, and have received satisfactory answers to these questions.  I willingly give 
my consent for participation in this research study.  (A copy of this consent form will be given to 
the person signing as the subject or as the subject’s authorized representative.) 
 
_____________________________________________________________ 
Participant’s Name (Print) 
 
_____________________________________________________________ 
Signature of Participant    Date  Time 
 
WITNESS:  I confirm that the contents of this consent document were orally presented, the 
participant or guardian indicates all questions have been answered to his or her satisfaction, and 
the participant or guardian has signed the document.  
 
 
_____________________________________________________________ 
Witness’s Name (Print) 
 
_____________________________________________________________ 
Signature of Witness      Date   
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PERSON ADMINISTERING CONSENT:  I have conducted the consent process and orally 
reviewed the contents of the consent document. I believe the participant understands the 
research. 
 
_____________________________________________________________ 
Person Obtaining Consent (Print) 
 
_____________________________________________________________ 
Signature of Person Obtaining Consent        Date 
 
 
 
_____________________________________________________________ 
Principal Investigator’s Name (Print) 
 
_____________________________________________________________ 
Signature of Principal Investigator          Date 
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APPENDIX C:  PERSONAL HISTORY FORM 
 
PERSONAL HISTORY FORM                                                           (version 2-17-09) 
 
Technician _______________________    Contract ________________  ID _________ 
 
   PLEASE PRINT AND FILL OUT  COMPLETELY  
 
1. Name: ______________________________  Date: ___________________ 
 Phone#: (home) ____________________ (work) ________________________ 
 Address: __________________________________________________________ 
 City: _______________________ State ___________  Zip ______________ 
 e-mail address (if available):___________________________________________ 
2. Employer: ________________________________________________________ 
 Occupation: _______________________________________________________ 
 
3. Date of Birth: ________________ Sex: _______   Age: _______ Race:  _______ 
 
4.  General Medical History                    Circle one  
Any medical  complaints presently?    (if yes, explain) ....                                     yes    no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Any major illnesses in the past?  (if yes, explain) ..... (date) ______         yes   no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Any hospitalization or surgery?  (if yes, explain)  ......    (date)  _________          yes    no 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
 
Have you ever had an EKG (electrocardiogram) ? ......    (date)  _________         yes    no 
 
 
Are you diabetic?  ....If yes, at what age did you develop diabetes: _________    yes    no 
 
Are you currently taking any medications? .............................          yes    no 
 
Medication  Dosage Reason  Times taken per day 
______________________________________________________________________ 
______________________________________________________________________ 
 
5.  Family History 
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  Age if    Age of   Cause of 
  alive    death   death 
Father  ______   ________ ____________________ 
Mother ______   ________ ____________________ 
 
 
 
Do you have a family history of: (Blood relatives only: give age of occurrence if applicable) 
       Relationship   Age of 
           occurrence 
--High blood pressure ...... yes    no   ______________________________ 
--Heart attack.....................yes    no   ______________________________ 
--By-pass surgery...............yes    no   ______________________________ 
--Stroke..............................yes    no   ______________________________ 
--Diabetes...........................yes    no               ______________________________ 
--Gout.................................yes    no   ______________________________ 
--Obesity.............................yes    no              ______________________________ 
 
6.  Tobacco History  (check one) 
_____   None       Cigarette history 
_____   Quit months/years ago    _____   1-10 daily 
_____   Cigarette      _____    11-20 “ 
_____   Snuff       _____    21-30 “ 
_____   Chewing tobacco      _____    31-40   “ 
_____   Pipe       _____    more than 40 
Total years of tobacco use? _______     
 
Snuff history       Chewing history  
______   < 0.5 cans daily     _____   < 0.5 pouches daily 
______   0.5-2.5 cans  “     _____   0.5-2.5 pouches  “ 
______   > 2.5 cans     “      _____   > 2.5 pouches     “ 
 
7. Weight History  
What do you consider a good weight for you? ________ Weight at age 21? _________ 
Weight since age 21? ________    Weight one year ago? ______ 
Weight now? ________ 
 
8. Cardio-Respiratory History 
 
Any heart disease now?..........................................................................................    yes  no 
 
Any heart disease in the past?................................................................................  yes  no 
 
Heart murmur?........................................................................................................ yes  no 
 
Occasional chest pains?........................................................................................    yes  no 
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Chest pains on exertion?.........................................................................................  yes  no 
 
Fainting?.................................................................................................................  yes  no 
 
Daily coughing?.....................................................................................................  yes  no 
 
Cough that produces sputum?............................................................................... . yes  no 
 
High blood pressure?.............................................................................................  yes  no 
 
Shortness of breath -- 
 at rest.......................................................................................................    yes  no 
 lying down..............................................................................................    yes  no 
 sleeping at night.....................................................................................    yes  no 
 after 2 flights of stairs...........................................................................     yes  no 
 
9.  Muscular  History 
 
Any muscle injuries or illnesses now?................................................................    yes  no 
 
Any muscle injuries in the past?.........................................................................    yes  no 
 
Muscle pain at rest?............................................................................................    yes  no 
 
Muscle pain on exertion?...................................................................................    yes  no 
 
10.  Bone-Joint History 
 
Any bone or joint (including spinal) injuries or illnesses now?........................    yes  no 
 
Any bone or joint (including spinal) injuries or illnesses in the past?..............    yes  no 
 
Ever had painful joints?....................................................................................   yes  no 
 
Ever had swollen joints?..................................................................................    yes  no 
 
Flat feet?...........................................................................................................   yes  no 
 
11.  Menstrual History (Women only) 
 
Are you post-menopausal (e.g., not had menstrual flow for at least one year)? ... yes  no 
 
Have you had a hysterectomy? .............................................................................    yes  no 
 
If you have had a hysterectomy, were the ovaries removed? ………………......    yes  no 
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If pre-menopausal:  On what date did your last period start (beginning of flow)? ____________ 
 Are your periods regular? .....................................................    yes  no 
Approximately how many days apart are your periods?      _____________ 
Are you on any hormonal supplements, such as a birth control pill or 
estrogen replacement therapy? .............................................................................    yes  no 
 If so, what? ________________________________ 
 
12.  Nutritional Survey 
How many times do you usually eat per day?                                                   ________ 
 
What time of day do you eat your largest meal?                                               ________ 
 
How many times per week do you usually eat...     
 ____ Hamburger ____ Sausage  ____ Bacon 
 ____ Beef  ____ Pork  ____ Cheese 
 ____ Shellfish (shrimp, oysters, scallops, clams, etc.) 
 ____ Fish  ____Poultry  ____ Fried Foods 
 ____ Breads  ____ Cereals  ____ Vegetables 
 ____ Eggs  ____ Desserts  ____ Ice Cream 
 ____ Other 
 
How many servings per week do you usually consume? 
____ Whole milk   ____ Coffee 
____ Low-fat milk (2% milk fat) ____ Tea 
____ Skim milk (non-fat)  ____ Soft drinks 
____ Buttermilk   ____ Other 
 
 
 
 
 
13.  Physical Activity Survey 
a.  Compared to a year ago, how much regular physical activity do you currently get?  (Check 
One) 
 ____  much less  ____  somewhat less  ____  about the same 
 ____  somewhat more  ____  much more 
 
b.  For the last three months, have you been exercising on a regular basis?............  yes  no 
 
c.  What type of exercise or physical activity do you currently do or have done regularly in the 
past?   
     (For example:  walking, swimming, weight lifting, gardening, etc.)  
______________________________________________________________________________
______________________________________________________________________________
____________________________________________________________ 
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d.  On the average, how many days per week do you exercise? _______ 
 
e.  How long do you exercise each time?  For how many minutes?  __________________ 
 
f.  How hard do you exercise on a scale from 1 to 5:  with 1 being easy and 5 being very hard? 
 ____ 1  ____ 2  ____ 3  ____ 4  ____ 5 
 
g.  Do you ever check your heart rate (pulse) to determine how hard you are exercising? 
 ____ yes ____ no 
 
h.  What aerobic activity or activities would you prefer in a regular exercise program for 
yourself? 
____ Walking and/or running  ____ Tennis   ____ Bicycling 
____ Racquetball   ____ Swimming  ____ Basketball 
____ Aerobic dance   ____ Stationary cycling ____ Soccer  
____ Stair climbing   ____ Rowing   ___________Other 
  
14.  Alcohol History 
Do you ever drink alcoholic beverages?    Yes ____  No ____  
If yes, what is your approximate intake of beverages per week?   
Beer _____ Wine _____ Mixed Drinks _____   
 
15.  Sleeping Habits 
Do you ever experience insomnia (trouble sleeping)? Yes ____ No ____ 
If yes, approximately how often?___________________________________________________ 
How many hours of sleep do you usually average per night?_____________________________ 
 
16.  Education 
Please indicate the highest level of education completed. 
____ Grade School  ____ Junior High  ____ High School  
____ College   ____ Graduate   ____ Postgraduate 
Please indicate degree earned (i.e. B.A., M.S., Ph.D.)_____________________________   
 
17.  Motivation or reason for participating in the testing program? 
____ General health and fitness evaluation 
____ Medical evaluation prior to starting and exercise program 
____ Baseline for weight loss 
____ Required by supervisors or employers 
____ Other ______________________________________________________ 
 
18.  Family Physician 
Name:  _________________________________________________________ 
Address:________________________________________________________ 
Phone:  _________________________ 
Should it be necessary, may we send a copy of your results to your physician? 
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19.  Insurance  I, _____________________understand that this evaluation is not reimbursable 
under Medicare and the cost of the evaluation must be paid by me. 
 
Signature:  ________________________________ 
Date:  ___________________________________ 
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APPENDIX D:  DIETARY LOG FOR A TYPICAL DAY 
Date _________________    Subject ID # _____________ 
 
Dietary Log for a Typical Day 
 
Meal Time of 
day 
Serving 
Size 
Food Item Prepared by: 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
Please list all other vitamins, minerals, and supplements that you normally take in a day: 
___________________________________________________________________ 
_______________________________________________________________________ 
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APPENDIX E:  EXPERIMENTAL SESSION INSTRUCTIONS 
Age-related Changes in Skeletal Muscle Signaling after Acute Heavy 
Resistance Exercise 
 
Principal Investigator:  Scott E. Gordon, Ph.D. 
Telephone #:  (252) 737-2879 
Sub Investigators:  Hope Tharrington/Jen Macesich/Eric Choplin 
Telephone #:  (252) 883-2001/ (919) 606-2853/(919) 671-1482 
 
EXPERIMENTAL SESSION INSTRUCTIONS 
 
Human Performance Laboratory 
 
 
 
For three full days prior to session (Start Date: ): 
 1. Do not drink alcohol. 
 2. If you consume caffeine, do so only in moderation. 
 3. Drink at least 64 oz. of water per day (i.e., eight 8-oz. glasses). 
  
On day of experimental session (Date: ): 
 1. Drink 16 oz. of water before reporting to the laboratory. 
 2. **Do not eat or drink anything but water for the 12 hours prior to reporting to the laboratory!! 
 3. **Do not exercise before the experimental session!! 
 4. Report to the East Carolina Heart Institute at _________________.   
 5. Wear exercise clothes, specifically shorts and athletic shoes, to the experimental session. 
 
For the duration of the experiments: 
 1. Do not engage in exercise. 
 2. Do not donate blood or plasma. 
 3. If you begin taking new medications, please notify Hope Tharrington/Jen Macesich/Eric Choplin. 
 
 
 
 
 
 
 
  
  
 
